Search research articles
Contact Us
Filters
Showing results (1-10 of 76) with videos related to
Page
of 8
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 10, 2013
Long-lasting recombinant factor VIII proteins for hemophilia A
Amy D Shapiro
Vascular Health and Risk Management
|
December 15, 2007
Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A
Amy D Shapiro
Clinical Advances in Hematology & Oncology : H&O
|
September 30, 2008
Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors
Amy D Shapiro
Blood Advances
|
February 11, 2021
Concizumab: a novel anti-TFPI therapeutic for hemophilia
Amy D Shapiro
F1000Research
|
August 22, 2019
Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia
Nihal Bakeer, Amy D Shapiro
Therapeutic Advances in Drug Safety
|
August 2, 2014
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes
Amy D Shapiro, Ulla Hedner
Lancet (London, England)
|
March 30, 2012
Modern haemophilia care
Erik Berntorp, Amy D Shapiro
Blood
|
March 16, 2025
How I treat type 1 plasminogen deficiency
Amy D Shapiro, Charles Nakar
Journal of Blood Medicine
|
February 25, 2025
Emerging Therapies in Hemophilia: Improving Equitable Access to Care
Magdalena Lewandowska, Sonia Nasr, Amy D Shapiro
Blood
|
February 26, 2015
Rare bleeding disorders: diagnosis and treatment
Roberta Palla, Flora Peyvandi, Amy D Shapiro
Page
of 8
Search research articles
Search
Showing results (1-10 of 76) with videos related to
Sort By:
Page
of 8
Hematology. American Society of Hematology. Education Program
|
December 10, 2013
Long-lasting recombinant factor VIII proteins for hemophilia A
Amy D Shapiro
Vascular Health and Risk Management
|
December 15, 2007
Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A
Amy D Shapiro
Clinical Advances in Hematology & Oncology : H&O
|
September 30, 2008
Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors
Amy D Shapiro
Blood Advances
|
February 11, 2021
Concizumab: a novel anti-TFPI therapeutic for hemophilia
Amy D Shapiro
F1000Research
|
August 22, 2019
Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia
Nihal Bakeer, Amy D Shapiro
Therapeutic Advances in Drug Safety
|
August 2, 2014
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes
Amy D Shapiro, Ulla Hedner
Lancet (London, England)
|
March 30, 2012
Modern haemophilia care
Erik Berntorp, Amy D Shapiro
Blood
|
March 16, 2025
How I treat type 1 plasminogen deficiency
Amy D Shapiro, Charles Nakar
Journal of Blood Medicine
|
February 25, 2025
Emerging Therapies in Hemophilia: Improving Equitable Access to Care
Magdalena Lewandowska, Sonia Nasr, Amy D Shapiro
Blood
|
February 26, 2015
Rare bleeding disorders: diagnosis and treatment
Roberta Palla, Flora Peyvandi, Amy D Shapiro
Page
of 8